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Objectives. The goal of our study was to investigate the prevalence of prostate cancer in an unselected population of Senegalese
men. Patients and Methods. We conducted the study over two years (2008 and 2009) on an unselected population of 572 Senegalese
men, aged 35 and older. The following parameters have been investigated: the subject’s age, the presence or absence of urination
disorders,thefamily’shistoryofprostatecancerorprostatesurgery,theaspectsoftheprostateondigitalrectalexamination(DRE),
the total PSA level, and the outcomes of the prostate biopsies. Data entry was performed with Epi Info 6 software and was analyzed
and recorded using Excel software. We performed mean and frequency calculations. Results. The mean age of our patients was 65.5
years, with extremes of 38 and 93 years. Age groups from 50 to 59 and from 60 to 69 were the most represented. DRE was normal
in the age group from 35 to 39, and only one patient in the age group from 40 to 49 had a prostate nodule. PSA level was greater
than or equal to 4ng/mL in 66 cases. A total of 5.4% patients had a PSA level greater than or equal to 10ng/mL. Only two patients
in the age group from 40 to 49 had a PSA level greater than 4ng/mL. Of the 72 biopsies we performed, prostatic adenocarcinoma
was found in 30.6% of the cases. It is the only type of prostate cancer we found in our series. The cases of prostate cancer were
mostly observed in the age groups from 60 to 69 and from 70 to 79. No cases were detected for ages younger than 50. DRE gave
indications of possible adenocarcinoma in 27.30% cases. Its sensitivity was 27%, while its positive predictive value was estimated
at 35%. Of all positive biopsies, 4.5% had a PSA level between 0 and 3.9ng/mL. In this case, the sensitivity of PSA was 95.5%,
and the positive predictive value was 31.8%. High-grade intraepithelial neoplasiae were observed in 21 cases. Conclusion.P r o s t a t e
cancer is frequent in Senegal, and screening remains the best way for early diagnosis.
1.Introduction
The early detection and treatment of prostate cancer con-
tinues to pose multiple debates. Early detection of certain
c a n c e r sa l l o w sf o rah i g h e r ,m o r ep r o d u c t i v et r e a t m e n t
program. Detection is based on digital rectal examination
(DRE) and the determination of prostate-speciﬁc antigen
(PSA) levels. It is recommended to begin screening for
detection of prostate cancer at the age of 50 in men with
more than 10 years of life expectancy, and at the age of 45 in
men with a familial history of prostate cancer [1]. While in
developedcountries,themortalityrateofprostatecancerhas
declined signiﬁcantly thanks to early detection; in Africa, the
diagnosis is most often delayed because patients only consult
in cases of urinary disorders, resulting in 80% of cases being
diagnosed in a metastatic state [2]. The aim of our study was
thus to investigate the prevalence of prostate cancer in an
unselected population of Senegalese men to propose an early
detection system for localized forms.
2. Patients andMethods
We conducted a prospective study, over two years (2008
and 2009), on an unselected Senegalese population of male
patients. Our study included 572 patients whose age was
greater than or equal to 35. We investigated the following
parameters:
(i) the subject’s age,
(ii) the presence or absence of urination disorders,
(iii) the family’s history of prostate cancer or prostate
surgery,2 ISRN Oncology
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Figure 2: Results of prostate biopsies.
(iv) the appearance of the prostate on digital rectal
examination,
(v) the total PSA level,
(vi) the outcome of the prostate’s biopsy.
T h ed a t ae n t r yw a sp e r f o r m e dw i t hE p iI n f o6s o f t w a r e .
ThedatawasanalyzedandrecordedusingExcelsoftware.We
performed both mean and frequency calculations.
3. Results
The mean age of our patients was 65.5 years, with extremes
of 38 and 93 years. Age groups from 50 to 59 and from 60
to 69 were the most highly represented. Figure 1 shows the
distribution of patients according to age groups.
The various aspects of the prostate on DRE are shown
in Table 1. The prostate was benign in 54.9% of the cases.
DRE was normal in the age group from 35 to 39, and only
one patient in the age group from 40 to 49 had a prostate
nodule. A total of 21.5% of participants had a PSA level
greater than or equal to 4ng/mL, which represented 66 cases.
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Figure 3: Distribution of adenocarcinoma by age.
Table 1: Aspect of the prostate on digital rectal examination
depending on age.
Age Normal Hbp Indurated Nodular
<4 0 3000
40–49 67 24 0 1
50–59 127 111 2 1
60–69 35 129 8 0
70–79 6 46 1 3
>7 9 3401
Total 241 314 11 6
In addition, 5.4% of patients had a PSA greater than or equal
to 10ng/mL. Only two patients in the age group of 40 to
49 had a PSA level greater than 4ng/mL. The distribution
of PSA levels as a function of age is reported in Table 2.
Of the 72 biopsies we performed, prostatic adenocarcinoma
accounted for 30.6% of them. It is the only type of prostate
cancer we found in our series. Other histological lesions were
associated with prostate cancer (Figure 2). The distribution
of histological lesions according to age groups is reported in
Table 3. The cases of prostate cancer were mostly observed
in the age groups from 60 to 69 and from 70 to 79. No
c a s ew a sd e t e c t e df o rm e ny o u n g e rt h a n5 0( Figure 3). DRE
was suspicious in 27.3% of cases. Its sensitivity was of 27%,
while its positive predictive value was estimated as 35%.
Four and one-half percent of all positive biopsies had PSA
levels between 0 and 3.9ng/mL. When PSA levels were above
30ng/mL, the detection rate was 36.36%. The sensitivity of
PSA levels was 95.5%, and the positive predictive value was
31.8%. High-grade intraepithelial neoplasiae were associated
in 12 cases with adenomyoma injuries or chronic prostatitis
lesions. However, they were only isolated in nine cases. These
high-grade lesions were observed in 21 cases, of which the
age group from 60 to 69 was the most represented.ISRN Oncology 3
Table 2: PSA level distribution depending on age.
Age 0–3.9ng/mL 4–9.9ng/mL 10–19.9ng/mL 20–29.9ng/mL >30ng/mL
<3 9 3000 0
40–49 90 1 1 0 0
50–59 228 12 0 0 1
60–69 140 18 7 5 3
70–79 40 3 5 0 7
>8 0 5120 0
Total 506 35 15 5 11
Table 3: Distribution of histological lesions depending on age.
Age Adenocarcinoma Adenomyoma
Adenomyoma
+ high-grade
PIN
Adenomyoma
+ chronic
prostatitis
Low-grade
PIN
High-grade
PIN
High-grade
PIN + chronic
prostatitis
<4 0 0 0 00000
4 0 – 4 9 0 1 01000
5 0 – 5 9 2 5 11032
6 0 – 6 9 1 2 9 55231
7 0 – 7 9 7 2 21031
>7 9 1 2 00000
T o t a l 2 2 1 988294
4. Comments
In our study population, the prevalence of prostate cancer
was 3.8%. This prevalence is almost the same as observed in
Korea [3].Inourstudy,thedetectionrateofadenocarcinoma
on biopsy was 30.5%. Cosimo de Nunzio detected 30% of
adenocarcinoma in a series of biopsies with 12 samples sys-
tematicallycollected[4].Historically,DREhasbeenusedasa
method of early detection of prostate cancer. Any abnormal
DRE requires the performance of a prostate biopsy, even if
P S Al e v e l sa r en o r m a l[ 5]. The detection rate of prostate
cancer based on prostate biopsy when DRE is abnormal and
PSA levels are lower than 4ng/mL is variably reported in
the literature, ranging from 3% to 41% [6, 7]. Furthermore,
rectal examination is very operator dependent [8, 9]. Thus,
digitalexaminationoftheprostatebyDREisapoorlyreliable
method,withasensitivitylowerthan50%.Normalexamina-
tion does not eliminate the possibility of a cancer. However,
when associated with PSA levels, its predictive value is
increased, and thus our decision to use it as a screening tool
in our study. This is also the case in other studies performed
in Europe, Asia, and United States [1, 3]. The impact of
isolated prostatic intraepithelial neoplasia (PIN) lesions on
prostate biopsies is not clear and varies from 0.7 to 19%,
depending on the population studied (general population
versus population with urological pathologies), the degree
of severity considered, and the country selected [10, 11]. In
the study by Parkinson [12] and Wills et al. [13], 439 sets
of sextant biopsies performed with an 18-gauge needle were
reviewed, and the diagnosis of high-grade PIN was discov-
ered in 5.5% of these series of biopsies. In the study by Bost-
wick, the incidence of isolated high-grade PIN was 16.5%
[14]. In our study population, the PIN incidence was 29.1%.
According to some authors, prostatic intraepithelial neo-
plasia lesions constitute precancerous lesions [11–16]. The
prevalence of PIN lesions increases with age, and it appears
that there is a ﬁve-year gap before cancer onset [17, 18].
5. Conclusion
Prostate cancer is diagnosed at advanced stage in our coun-
tries; screening must be recommended for early diagnosis
and curative treatment.
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